RxDoctor Payments DataLook up a doctor →

Danko Martincic, MD

Hematology & Oncology · Post Falls, IDNPI 1124071592

Payments from drug & device makers

$3,454,025in general payments, 2019–2025

Across 1,763 payments — averaging $1959.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$1M
  • Merck$767K
  • E.r. Squibb & Sons, L.L.C.$420K
  • AstraZeneca$262K
  • G1 Therapeutics, Inc.$198K
  • AbbVie$151K
  • plus $642K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited9$1,012,248
Merck103$767,371
E.r. Squibb & Sons, L.L.C.321$419,888
AstraZeneca198$262,482
G1 Therapeutics, Inc.183$198,439
AbbVie41$150,703
Daiichi Sankyo Inc.97$131,100
Regeneron11$73,537
Seagen Inc.62$64,911
Pfizer70$50,570
Regeneron Healthcare Solutions, Inc.49$44,180
GSK34$42,269
Bristol Myers Squibb81$36,363
Sanofi45$32,055
Deciphera Pharmaceuticals Inc.13$28,080
EMD Serono, Inc.27$25,307
Astellas Pharma US Inc26$24,336
Bayer28$21,923
Boehringer Ingelheim24$17,095
Mirati Therapeutics, Inc.7$14,019
Gilead(2 entities)16$7,719
Ares Trading SA9$7,250
Beigene USA, Inc.12$4,209
Lilly USA, LLC12$4,092
Johnson & Johnson40$2,474
Astellas Pharma Global Development2$2,010
Servier Pharmaceuticals LLC5$1,896
Morphosys, US Inc.3$1,195
Exelixis Inc.21$1,143
Novartis55$734
Genentech USA, Inc.21$398
Eisai Inc.14$295
Amgen8$283
AVEO Pharmaceuticals, Inc.8$213
Dendreon Pharmaceuticals LLC7$212
Legend Biotech USA Inc.4$183
ADC Therapeutics America, Inc.3$178
Ipsen Biopharmaceuticals, Inc6$163
Galvanize Therapeutics, Inc1$145
Array Biopharma Inc8$139
Foundation Medicine, Inc.3$134
Karyopharm Therapeutics Inc.2$129
Telix Pharmaceuticals1$125
Shire North American Group Inc1$125
Blueprint Medicines Corporation5$124
Myriad Genetic Laboratories, Inc.5$111
Puma Biotechnology, Inc.6$110
Jazz Pharmaceuticals Inc.5$101
Novocure Inc.1$90
Pharmacyclics LLC, An Abbvie Company4$84
Pharmacosmos Therapeutics Inc.4$82
Acrotech Biopharma Inc.4$80
Rigel Pharmaceuticals, Inc.4$77
Stemline Therapeutics Inc.3$74
Ascendis Pharma Endocrinology Inc1$72
Adaptive Biotechnologies Corporation3$58
Takeda Pharmaceuticals U.S.A., Inc.2$55
Sumitomo Pharma America, Inc.2$46
Incyte Corporation2$45
Kedrion Biopharma, Inc.1$44

How this compares

$3,454,025 in reported general payments places this provider in the 95th percentile of 34 hematology & oncology providers in Idaho.

See all hematology & oncology providers in Idaho →

Medicare billing

Part B allowed, 2024
$7,544,999
Medicare patients
474
Services billed
315,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Post Falls

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →